Trithiocarbonates as a Novel Class of HDAC Inhibitors: SAR Studies, Isoenzyme Selectivity, and Pharmacological Profiles
作者:Florian Dehmel、Steffen Weinbrenner、Heiko Julius、Thomas Ciossek、Thomas Maier、Thomas Stengel、Kamal Fettis、Carmen Burkhardt、Heike Wieland、Thomas Beckers
DOI:10.1021/jm800093c
日期:2008.7
Inhibitors of histone deacetylases (HDAC) are currently developed for the treatment of cancer. These include compounds with a sulfur containing head group like depsipeptide, alkylthiols, thiocarboxylates, and trithiocarbonates with a carbonyl group in the alpha-position. In the present investigation, we report on the synthesis and comprehensive SAR analysis of HDAC inhibitors bearing a tri- or dithiocarbonate
目前已开发出组蛋白脱乙酰基酶(HDAC)抑制剂来治疗癌症。这些包括具有含硫头基的化合物,例如二肽,烷基硫醇,硫代羧酸盐和在α位具有羰基的三硫代碳酸酯。在本研究中,我们报告了带有三硫代或二硫代碳酸酯基序的HDAC抑制剂的合成和综合SAR分析。这样的三硫代碳酸酯可容易地从预制的或原位制备的α-卤代甲基芳基酮获得。显示了已定义类似物的HDAC同种型选择性和底物竞争作用模式。对头基的探索表明,有效抑制HDAC的必要条件是使用二硫代α-羰基基序。确定了高效,底物竞争性HDAC6选择性抑制剂(12ac:IC 50 = 65 nM,K i = 110 nM)。具有氨基喹啉取代的吡啶基-硫代乙酰基帽的三硫代碳酸酯类似物显示出与作为批准的抗癌药物的亚磺酰苯胺异羟肟酸(SAHA)相当的细胞毒性谱和效能。